LEO Pharma: Clinical Trials

50 completed, 5 terminated, 3 recruiting. 58 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	58	Completed 50, Terminated 5, Recruiting 3
Phase 2	2	Completed 2

Follow LEO Pharma: new trials by email

Trials (filtered) newest first · largest first

All 58 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus Delgocitinib, Cream Vehicle - Lichen Sclerosus	Phase 3	Recruiting	LEO Pharma	652	2026-05-01	2026-10-13
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum Spesolimab, Placebo matching to spesolimab, Prednisone - Pyoderma Gangrenosum	Phase 3	Recruiting	LEO Pharma	90	2025-02-05	2026-10-23
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis Tralokinumab + TCS, Placebo + TCS - Atopic Dermatitis	Phase 3	Recruiting	LEO Pharma	195	2024-06-10	2026-07-07
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Delgocitinib, Vehicle cream - Chronic Hand Eczema	Phase 3	Completed	LEO Pharma	362	2023-09-05	2025-09-25
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy Tralokinumab, Placebo - Atopic Dermatitis, Atopic Hand Eczema	Phase 3	Completed	LEO Pharma	235	2023-08-28	2026-10-22
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis LEO 90100, Daivobet® ointment - Stable Plaque Psoriasis	Phase 3	Completed	LEO Pharma	604	2023-06-21	2026-04-06
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer Tinzaparin - Colorectal Cancer Metastatic, Thromboembolism	Phase 3	Completed	Galician Research Group on Digestive Tumors	232	2023-03-02	2025-08-22
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis Brodalumab, Ustekinumab, Placebo - Psoriasis	Phase 3	Terminated	LEO Pharma	12	2022-12-07	2025-03-14
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema Delgocitinib, Cream vehicle - Chronic Hand Eczema	Phase 3	Completed	LEO Pharma	98	2022-07-14	2026-08-21
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis TMB-001, Matching Vehicle - Ichthyosis	Phase 3	Completed	LEO Pharma	153	2022-06-21	2026-05-22
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema Delgocitinib, Toctino - Chronic Hand Eczema	Phase 3	Completed	LEO Pharma	513	2022-06-15	2025-05-09
Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) Tralokinumab - Atopic Dermatitis	Phase 3	Completed	LEO Pharma	136	2022-01-13	2025-03-11
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials Delgocitinib - Chronic Hand Eczema	Phase 3	Completed	LEO Pharma	801	2021-08-23	2025-04-08
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) Delgocitinib cream, Cream vehicle - Chronic Hand Eczema	Phase 3	Completed	LEO Pharma	473	2021-05-25	2025-04-08
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema Delgocitinib cream, Cream vehicle - Chronic Hand Eczema	Phase 3	Completed	LEO Pharma	487	2021-05-10	2025-04-08
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis Tralokinumab, Placebo, Topical corticosteroids (TCS) - Atopic Dermatitis	Phase 3	Completed	LEO Pharma	106	2020-10-27	2025-03-11
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris LEO 90100 foam, Dovobet® ointment - Psoriasis Vulgaris	Phase 3	Completed	LEO Pharma	182	2019-01-24	2025-03-10
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 Tralokinumab, Placebo - Atopic Dermatitis	Phase 3	Completed	LEO Pharma	277	2018-12-13	2025-03-11
Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema Fucicort® Lipid cream, Fucidin® cream, Fucicort® Lipid cream vehicle - Infected Atopic Dermatitis/Eczema	Phase 3	Terminated	LEO Pharma	68	2018-07-31	2025-02-24
Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Tralokinumab, Placebos - Atopic Dermatitis	Phase 3	Completed	LEO Pharma	301	2018-06-19	2025-03-11

Showing 20 of 58. Sign in to see all of them.

Conditions studied

Dermatitis, Atopic (10)  ·  Keratosis, Actinic (9)  ·  Psoriasis (3)  ·  Eczema (2)  ·  Thromboembolism (2)  ·  Acne Vulgaris (1)  ·  Acute Chest Syndrome (1)  ·  Acute Lung Injury (1)  ·  Anemia (1)  ·  Anemia, Sickle Cell (1)  ·  Carcinoma (1)  ·  Carcinoma, Squamous Cell (1)  ·  Colorectal Neoplasms (1)  ·  Hemorrhage (1)  ·  Ichthyosis (1)

Interventions

tralokinumab (10)  ·  calcipotriene (9)  ·  Tinzaparin (5)  ·  betamethasone-17,21-dipropionate (5)  ·  delgocitinib (5)  ·  Betamethasone (3)  ·  3-ingenyl angelate (2)  ·  Hydrocortisone (2)  ·  Adrenal Cortex Hormones (1)  ·  Alitretinoin (1)  ·  Cryotherapy (1)  ·  Dalteparin (1)  ·  Gels (1)  ·  LEO 43204 (1)  ·  Molasses (1)

Countries

Canada (29)  ·  France (25)  ·  United States (23)  ·  Germany (22)  ·  United Kingdom (21)  ·  Spain (17)  ·  Poland (16)  ·  Belgium (14)  ·  Italy (11)  ·  Japan (8)  ·  Netherlands (8)  ·  Denmark (7)  ·  Australia (5)  ·  China (5)  ·  Norway (4)

Top investigators

C. William Hanke, MD (2)  ·  Mark Lebwohl, MD (2)  ·  Michael Bukhalo, MD (2)  ·  Agnes Y. Y. Lee, MD, MSc, FRCPC (1)  ·  Akira Ozawa, MD, Professor (1)  ·  Alan Menter, MD (1)  ·  Alicia Bucko, MD (1)  ·  Amy M Morris, MD (1)  ·  Andreas Wollenberg, Prof. Dr. med. (1)  ·  Andrew King, MD (1)  ·  Armand Mekontso Dessap, MD, PhD (1)

Results publications

PMID 40555305, PMID 41118053, PMID 36152216, PMID 40085349, PMID 32785881, PMID 33000465, PMID 34397196, PMID 37682422, PMID 37804473, PMID 39033766, PMID 40081663, PMID 41240207, PMID 41775339, PMID 16458642, PMID 19067709, PMID 19713451, PMID 20633284, PMID 23764005, PMID 24509965, PMID 24918567, PMID 26244354, PMID 26284719, PMID 26300464, PMID 26659941, PMID 27531752, PMID 27714595, PMID 28236223, PMID 29618162, PMID 32965655, PMID 33779986, PMID 34339017, PMID 34878173, PMID 35297108, PMID 35671038, PMID 35857179, PMID 36473633, PMID 37074705, PMID 38189593, PMID 38485862, PMID 38507100, PMID 38563683, PMID 40209087, PMID 40252681, PMID 40681936, PMID 40721559, PMID 40879371, PMID 41102518, PMID 41249955, PMID 41642555, PMID 41850772

NIH funding

2017 (3), 2016 (2), 2009 (1), 2018 (1), 2019 (1), 2023 (1), 2025 (1)